Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ergocalciferol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 4/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 2/20 | 1.00 |
| ▸ | AR | P10275 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | TST | Q16762 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.71 |
| ▸ | PGR | P06401 | 3/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ergocalciferol SCHEMBL12346036 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL3421 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL12322071 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL3228635 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24855744 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL4140479 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL24565106 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL9980609 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL3420 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 | |
| Ergocalciferol SCHEMBL20510995 | 1.00 | ALDH1A1 (1.00) | ALDH1A1ALOX15CYP3A4LMNAHSPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160272729-A1 | METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT | EPSHTEIN OLEG ILIICH (RU) | 2016-09-22 | — | — | US | disclosed |
| US-20160229914-A1 | METHOD OF TREATING A PATHOLOGICAL SYNDROME | EPSHTEIN OLEG ILIICH (RU) | 2016-08-11 | — | — | US | disclosed |
| US-9382332-B2 | Method of treating a pathological syndrome and a pharmaceutical agent | OLEG ILIICH EPSHTEIN (RU) | 2016-07-05 | — | — | US | disclosed |
| US-20160184256-A1 | METHOD OF TREATING DISORDERS OF THE CARDIOVASCULAR SYSTEM AND A PHARMACEUTICAL AGENT | EPSHTEIN OLEG ILIICH (RU) | 2016-06-30 | — | — | US | disclosed |
| US-20160176987-A1 | METHOD OF TREATING A PATHOLOGICAL SYNDROME AND A PHARMACEUTICAL AGENT | EPSHTEIN OLEG ILIICH (RU) | 2016-06-23 | — | — | US | disclosed |
| US-20160137750-A1 | METHOD OF TREATING A PATHOLOGICAL SYNDROME | EPSHTEIN OLEG IIIICH (RU) | 2016-05-19 | — | — | US | disclosed |
| US-9303091-B2 | Method of treating disorders of the cardiovascular system and a pharmaceutical agent | Epshtein, Oleg Iliich (RU) | 2016-04-05 | — | — | US | disclosed |
| US-9303090-B2 | Method of treating a pathological syndrome and a pharmaceutical agent | Epshtein, Oleg Iliich (RU) | 2016-04-05 | — | — | US | disclosed |
| US-9273117-B2 | Method for administering homeopathically potentized antibody | OLEG ILIICH EPSHTEIN (RU) | 2016-03-01 | — | — | US | disclosed |
| US-9228024-B2 | Method of treating hypertension disorder and a pharmaceutical agent | EPSHTEIN, OLEG I. (RU) | 2016-01-05 | — | — | US | disclosed |
| US-20100166762-A1 | METHOD OF TREATING A PATHOLOGICAL SYNDROME | Epshtein, Oleg Iliich (RU) | 2010-07-01 | — | — | US | disclosed |
| US-20080131440-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | Epshtein, Oleg I. (RU) | 2008-06-05 | — | — | US | disclosed |
| US-20080050360-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | EPSHTEIN, OLEG I. (RU) | 2008-02-28 | — | — | US | disclosed |
| US-20080050392-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | ILIICH EPSHTEIN O | 2008-02-28 | — | — | US | disclosed |
| US-20080025985-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | EPSHTEIN, OLEG I. (RU) | 2008-01-31 | — | — | US | disclosed |
| US-20080019982-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | EPSHTEIN, OLEG I. (RU) | 2008-01-24 | — | — | US | disclosed |
| US-20070224187-A1 | Method of treating a pathological syndrome and a pharmaceutical agent | EPSHTEIN, OLEG I. (RU) | 2007-09-27 | — | — | US | disclosed |
| US-7230101-B1 | Synthesis of methotrexate-containing heterodimeric molecules | GPC BIOTECH, INC. (US) | 2007-06-12 | — | — | US | disclosed |
| US-20030099636-A1 | Curing method for pathologic syndrome and medicinal preparation | EPSHTEIN, OLEG I. (RU) | 2003-05-29 | — | — | US | disclosed |
| EP-1295606-A1 | CURING METHOD FOR PATHOLOGIC SYNDROME AND A MEDICINAL PREPARATION | Epshtein, Oleg Iliich (RU) | 2003-03-26 | — | — | EP | disclosed |